Insights Blog @ Avulux
Avulux Added into the FDA-Funded Consortium for Technology & Innovation in Pediatrics (CTIP) Portfolio
Avulux, the innovator behind the only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, today announced that the Consortium for
Avulux and PECAA Partner to Bring Migraine Solution Lenses to Private Practices
Avulux, the maker of the only clinically proven migraine and light sensitivity lenses, and PECAA (Professional Eye Care Associates of America) are pleased to announce
Avulux Patient Feedback: Get Your Patients Back to What They Love
Migraine is a genetic neurological disease that affects nearly 48 million people in the United States — that’s almost 1 in 5 patients in your practice.
Avulux Proudly Partners with Opti-Port and PERC
Avulux is proud to announce formal partnerships with Opti-Port, the eye care industry’s only alliance of growth-oriented, multi-office eye care practices, and with PERC, a collective purchasing organization committed to helping optometric practices boost profitability.
A Neuro-Ophthalmologist’s Perspective On Migraine Prevalence In The Patient Population
Research shows that approximately 80 to 90 percent of patients with migraine report light sensitivity during attacks, and 49 percent report that light sensitivity is their most bothersome symptom during a headache.
Eyenavision And Avulux Introduce Chemistrie Avulux Clips For People Living With Migraine And Light Sensitivity
Eyenavision and Avulux today launched Chemistrie Avulux, an innovative new on-demand eyeglass clip option for people living with migraine and light sensitivity.